Levothyroxine is a synthetic thyroid hormone, used to treat hypothyroidism and related conditions. It has been a widely used and effective medication for many decades. The bioanalytical method is developed for the determination of endogenously present levothyroxine and its metabolite, liothyronine, in both stripped and un-stripped serum, using liquid chromatography-tandem mass spectrometry. Determining an endogenously present analyte is indeed a critical step in pharmacokinetic studies and determining the therapeutic dose of a drug. The term “stripped” typically refers to the removal of endogenous analytes that interfere with the accurate quantification of the analyte of interest. Method employed with, Kinetex® polar C18 (100 × 4.6 mm 2.6 μm) analytical column for chromatographic resolution by using, pump A as acetic acid in water and pump B as acetic acid in methanol. The mass spectrometer used with triple quadrupole operating in the positive ion mode, specifically using multiple reaction monitoring. Multiple reaction monitorin is a highly delicate and discriminating technique for quantifying specific analytes. The transitions are as follows: analyte transition: 777.55→731.65, metabolite transition: 651.70→605.85, IS analyteTransition: 780.60→734.75, and IS metaboliteTransition: 661.60→614.65. A resolution factor of 0.5 was achieved for levothyroxine and liothyronine. Linearity for levothyroxine in a range of 20.0–1000 ng/ml and liothyronine in a range of 0.3–15.0 ng/ml was employed. Method validation was performed to conduct stability studies and demonstrate the reproducibility for accuracy and reliability for LC-ESI-MS/MS assay. The proposed bioanalytical method is highly sensitive and selective, has a minimal processing volume, faster run time, no matrix impact, and the ability to measure analytes in different types of serum (stripped and normal). The method was valuable for both research and clinical laboratories and can provide reliable results.
Soni K, Agrawal GP. Simultaneous determination of levothyroxine and its metabolite liothyronine in human serum by using LC-ESI-MS/MS and its bioequivalence application. J Appl Pharm Sci. 2024. Online First. https://doi.org/10.7324/JAPS.2024.187582
1. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018 May;14(5):301-16. https://doi.org/10.1038/nrendo.2018.18 | |
2. Peterson SJ, McAninch EA, Bianco AC. Is a normal TSH synonymous with "euthyroidism" in levothyroxine monotherapy? J Clin Endocrinol Metabol. 2016 Dec 1;101(12):4964-73. https://doi.org/10.1210/jc.2016-2660 | |
3. Upadhyay U, Ashwinbhai Vora P, Patel R, Prajapati B. Levothyroxine sodium-thyroid hormone replacement therapy for hypothyroidism: a review of patent literature. Recent Pat Biotechnol. 2023 Sep 1;17(3):245-56. https://doi.org/10.2174/1872208317666221212124113 | |
4. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec 1;24(12):1670-751. https://doi.org/10.1089/thy.2014.0028 | |
5. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism and hypertension: fact or myth?-Authors' reply. Lancet. 2018 Jan 6;391(10115):30. https://doi.org/10.1016/S0140-6736(17)33321-4 | |
6. Nygaard B. 2012 ETA guidelines: the use of L-T4+ L-T3 in the treatment of hypothyroidism. Eur Thyr J. 2012;1(2):55-71. https://doi.org/10.1159/000339444 | |
7. Gowda GN, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev Mole Diagn. 2008 Sep 1;8(5):617-33. https://doi.org/10.1586/14737159.8.5.617 | |
8. US Food and Drug Administration; U.S. Department of Health and HumanServices; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CVM). Bioanalytical Method Validation: Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration: Silver Spring, MD, 2018. | |
9. Bertoncini CW, Palacios MJ, Fritz MC, Rodriguez MP, Acevedo C, Hunzicker GA, et al. Levothyroxine bioequivalence study and its narrow therapeutic index: comparative bioavailability results between two formulations available in Latin America. Adv Ther. 2023 Apr;40(4):1644-54. https://doi.org/10.1007/s12325-022-02352-6 | |
10. Nishant T, Sathish Kumar D, Arun Kumar PM. Role of pharmacokinetic studies in drug discovery. J BioequivAvailab. 2011;3:263-7. | |
11. Wang D, Stapleton HM. Analysis of thyroid hormones in serum by liquid chromatography-tandem mass spectrometry. Analytical and bioanalytical chemistry. 2010 Jul;397:1831-9. https://doi.org/10.1007/s00216-010-3705-9 | |
12. Dutt R, Malik KC, Karwa M, Jain GK. Development and validation of UPLC-MS/MS method for rapid simultaneous determination of levothyroxine and liothyronine in human serum. J Drug Deliv Ther. 2020 Jun 15;10(3-s):176-81. https://doi.org/10.22270/jddt.v10i3-s.4189 | |
Year
Month